115 related articles for article (PubMed ID: 3892705)
1. Cytosine arabinoside in experimental combination therapy.
Edelstein M; Valeriote F
Semin Oncol; 1985 Jun; 12(2 Suppl 3):75-83. PubMed ID: 3892705
[No Abstract] [Full Text] [Related]
2. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
3. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
[No Abstract] [Full Text] [Related]
4. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.
Estey E; Keating MJ; Plunkett W; McCredie KB; Freireich EJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):58-63. PubMed ID: 3473684
[No Abstract] [Full Text] [Related]
5. Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Arlin ZA
J Clin Oncol; 1985 Jan; 3(1):128. PubMed ID: 3838101
[No Abstract] [Full Text] [Related]
6. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
[No Abstract] [Full Text] [Related]
7. Studies on the cytotoxicity of cytosine arabinoside.
Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J
Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698
[No Abstract] [Full Text] [Related]
8. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
9. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of cytosine arabinoside in patients with acute myelogeneous leukemia.
Preusser P; Pielken HJ; Bauch HJ
Haematol Blood Transfus; 1987; 30():288-92. PubMed ID: 3476359
[No Abstract] [Full Text] [Related]
11. Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Lyytikäinen O; Elonen E; Lautenschlager I; Jokipii A; Tiittanen L; Ruutu P
Eur J Haematol; 1996 Mar; 56(3):188-9. PubMed ID: 8598243
[No Abstract] [Full Text] [Related]
12. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Ehninger G; Proksch B; Wanner T; Schuler U; Busch FW; Schmidt H; Schleyer E; Jaschonek K; Hiddemann W
Leukemia; 1992 Jun; 6(6):582-7. PubMed ID: 1602795
[TBL] [Abstract][Full Text] [Related]
13. DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
Gahrton G; Tidefelt U; Paul C; Björkholm M; Grimfors G; Hast R; Juliusson G; Järnmark M; Killander A; Kimby E
Leukemia; 1992; 6 Suppl 2():89-91. PubMed ID: 1578953
[No Abstract] [Full Text] [Related]
14. Reinduction chemotherapy for acute nonlymphocytic leukemia.
Letendre L; Kiely JM; Hoagland HC
Mayo Clin Proc; 1984 Sep; 59(9):618-21. PubMed ID: 6381915
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
Preisler HD; Rustum YM; Azarnia N; Priore R
Cancer Chemother Pharmacol; 1987; 19(1):69-74. PubMed ID: 3815728
[TBL] [Abstract][Full Text] [Related]
16. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
Paśnicki M
Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239
[No Abstract] [Full Text] [Related]
17. Occult testicular leukemia in a patient with acute monocytic leukemia.
Nishikawa A; Nobori U; Higashino H; Kobayashi Y
Pediatr Hematol Oncol; 1987; 4(4):349-51. PubMed ID: 3152942
[No Abstract] [Full Text] [Related]
18. Scheduling-dependent interaction for the combination of cytosine arabinoside and daunorubicin on HL-60 cells.
Bernabei PA; Rombolà G; Saccardi R; Bezzini R; Santini V; Pifferi C; Gattei V; Ferrini PR
Haematologica; 1988; 73(6):466-70. PubMed ID: 3148508
[No Abstract] [Full Text] [Related]
19. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G; David B; Reiffers J; Broustet A
Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
[TBL] [Abstract][Full Text] [Related]
20. Amsacrine with high-dose cytarabine in acute leukemia.
Zittoun R; Bury J; Stryckmans P; Lowenberg B; Peetermans M; Rozendaal KY; Haanen C; Kerkhofs M; Jehn U; Willemze R
Cancer Treat Rep; 1985 Dec; 69(12):1447-8. PubMed ID: 3841026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
